company background image
DPH

Dechra PharmaceuticalsLSE:DPH Stock Report

Market Cap

UK£5.5b

7D

-1.4%

1Y

52.3%

Updated

01 Dec, 2021

Data

Company Financials +
DPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance5/6
Financial Health5/6
Dividends0/6

DPH Stock Overview

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.

Dechra Pharmaceuticals Competitors

Merck

NYSE:MRK

US$189.2b

Zoetis

NYSE:ZTS

US$105.1b

IDEXX Laboratories

NasdaqGS:IDXX

US$51.6b

Elanco Animal Health

NYSE:ELAN

US$13.6b

Price History & Performance

Summary of all time highs, changes and price drops for Dechra Pharmaceuticals
Historical stock prices
Current Share PriceUK£50.50
52 Week HighUK£55.25
52 Week LowUK£31.32
Beta0.49
1 Month Change-1.17%
3 Month Change-4.36%
1 Year Change52.29%
3 Year Change134.01%
5 Year Change308.58%
Change since IPO3,725.76%

Recent News & Updates

Oct 15
It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

It would be hard to discount the role that CEO Ian Page has played in delivering the impressive results at Dechra...

Sep 25
Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Dechra Pharmaceuticals PLC ( LON:DPH ) has announced that it will be increasing its dividend on the 19th of November to...

Shareholder Returns

DPHGB PharmaceuticalsGB Market
7D-1.4%-1.1%-1.1%
1Y52.3%7.7%11.6%

Return vs Industry: DPH exceeded the UK Pharmaceuticals industry which returned 8.4% over the past year.

Return vs Market: DPH exceeded the UK Market which returned 10.9% over the past year.

Price Volatility

Is DPH's price volatile compared to industry and market?
DPH volatility
DPH Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: DPH is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: DPH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19971,798Ian Pagehttps://www.dechra.com

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.

Dechra Pharmaceuticals Fundamentals Summary

How do Dechra Pharmaceuticals's earnings and revenue compare to its market cap?
DPH fundamental statistics
Market CapUK£5.47b
Earnings (TTM)UK£55.50m
Revenue (TTM)UK£608.00m

98.6x

P/E Ratio

9.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DPH income statement (TTM)
RevenueUK£608.00m
Cost of RevenueUK£262.10m
Gross ProfitUK£345.90m
ExpensesUK£290.40m
EarningsUK£55.50m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Feb 21, 2022

Earnings per share (EPS)0.51
Gross Margin56.89%
Net Profit Margin9.13%
Debt/Equity Ratio47.8%

How did DPH perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

79%

Payout Ratio

Valuation

Is Dechra Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

98.59x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DPH (£50.5) is trading above our estimate of fair value (£37.03)

Significantly Below Fair Value: DPH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DPH is poor value based on its PE Ratio (98.6x) compared to the UK Pharmaceuticals industry average (30.3x).

PE vs Market: DPH is poor value based on its PE Ratio (98.6x) compared to the UK market (19x).


Price to Earnings Growth Ratio

PEG Ratio: DPH is poor value based on its PEG Ratio (6.4x)


Price to Book Ratio

PB vs Industry: DPH is overvalued based on its PB Ratio (8.6x) compared to the GB Pharmaceuticals industry average (4.5x).


Future Growth

How is Dechra Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

15.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DPH's forecast earnings growth (15.4% per year) is above the savings rate (0.9%).

Earnings vs Market: DPH's earnings (15.4% per year) are forecast to grow faster than the UK market (12.5% per year).

High Growth Earnings: DPH's earnings are forecast to grow, but not significantly.

Revenue vs Market: DPH's revenue (6.9% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: DPH's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DPH's Return on Equity is forecast to be low in 3 years time (19.8%).


Past Performance

How has Dechra Pharmaceuticals performed over the past 5 years?

18.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DPH has high quality earnings.

Growing Profit Margin: DPH's current net profit margins (9.1%) are higher than last year (6.6%).


Past Earnings Growth Analysis

Earnings Trend: DPH's earnings have grown by 18.2% per year over the past 5 years.

Accelerating Growth: DPH's earnings growth over the past year (63.7%) exceeds its 5-year average (18.2% per year).

Earnings vs Industry: DPH earnings growth over the past year (63.7%) exceeded the Pharmaceuticals industry -20.6%.


Return on Equity

High ROE: DPH's Return on Equity (8.8%) is considered low.


Financial Health

How is Dechra Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: DPH's short term assets (£392.2M) exceed its short term liabilities (£155.8M).

Long Term Liabilities: DPH's short term assets (£392.2M) do not cover its long term liabilities (£425.4M).


Debt to Equity History and Analysis

Debt Level: DPH's net debt to equity ratio (29.1%) is considered satisfactory.

Reducing Debt: DPH's debt to equity ratio has reduced from 56.4% to 47.8% over the past 5 years.

Debt Coverage: DPH's debt is well covered by operating cash flow (29.4%).

Interest Coverage: DPH's interest payments on its debt are well covered by EBIT (9.9x coverage).


Balance Sheet


Dividend

What is Dechra Pharmaceuticals's current dividend yield, its reliability and sustainability?

0.80%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DPH's dividend (0.8%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.38%).

High Dividend: DPH's dividend (0.8%) is low compared to the top 25% of dividend payers in the UK market (4.17%).


Stability and Growth of Payments

Stable Dividend: DPH's dividends per share have been stable in the past 10 years.

Growing Dividend: DPH is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DPH is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Ian Page (60 yo)

20yrs

Tenure

UK£2,624,000

Compensation

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since 1997. Mr....


CEO Compensation Analysis

Compensation vs Market: Ian's total compensation ($USD3.49M) is above average for companies of similar size in the UK market ($USD2.16M).

Compensation vs Earnings: Ian's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: DPH's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: DPH's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DPH insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Dechra Pharmaceuticals PLC's employee growth, exchange listings and data sources


Key Information

  • Name: Dechra Pharmaceuticals PLC
  • Ticker: DPH
  • Exchange: LSE
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£5.466b
  • Shares outstanding: 108.35m
  • Website: https://www.dechra.com

Number of Employees


Location

  • Dechra Pharmaceuticals PLC
  • 24 Cheshire Avenue
  • Cheshire Business Park
  • Northwich
  • Cheshire
  • CW9 7UA
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 21:52
End of Day Share Price2021/12/01 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.